Celebrex

Celebrex. It is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The medication functions as a selective cyclooxygenase-2 (COX-2) inhibitor, distinguishing it from traditional NSAIDs. It is available by prescription in numerous countries and has been the subject of significant clinical and regulatory scrutiny since its introduction.

Medical uses

It is indicated for the relief of symptoms associated with osteoarthritis and rheumatoid arthritis in adults. It is also approved for the management of acute pain, such as that following dental surgery or orthopedic procedures, and for the treatment of primary dysmenorrhea. In certain jurisdictions, it is used for patients with ankylosing spondylitis and juvenile rheumatoid arthritis. Clinical trials, such as those reviewed by the Food and Drug Administration, have demonstrated its efficacy in reducing pain and improving physical function compared to placebo. Its use is generally considered when patients have a history of gastrointestinal intolerance to other NSAIDs like ibuprofen or naproxen.

Adverse effects

Common adverse effects include dyspepsia, diarrhea, and abdominal pain. Serious risks, which led to intense scrutiny by regulatory bodies like the Food and Drug Administration and the European Medicines Agency, include an increased incidence of major adverse cardiovascular events, such as myocardial infarction and stroke. Other significant risks are serious gastrointestinal events like bleeding, ulceration, and perforation, as well as renal impairment and severe skin reactions such as Stevens-Johnson syndrome. The National Institutes of Health has published data from studies like the Adenoma Prevention with Celecoxib trial highlighting these risks. It carries a black box warning in the United States regarding cardiovascular and gastrointestinal risks.

Pharmacology

It acts as a selective inhibitor of the cyclooxygenase-2 (COX-2) isoenzyme. This enzyme is responsible for the synthesis of prostaglandins that mediate inflammation, pain, and fever. By sparing the cyclooxygenase-1 (COX-1) enzyme, it aims to reduce the risk of gastrointestinal toxicity associated with non-selective NSAIDs. It is extensively metabolized in the liver primarily by the cytochrome P450 enzyme CYP2C9, and its pharmacokinetics can be affected by inhibitors of this enzyme, such as fluconazole. The drug is highly protein-bound, primarily to albumin, and has a terminal half-life of approximately 11 hours.

History

It was co-developed by the pharmaceutical companies Searle and Pfizer. It received approval from the Food and Drug Administration on December 31, 1998, becoming the first selective COX-2 inhibitor approved in the United States. Its market position was significantly impacted by the voluntary withdrawal of its competitor, rofecoxib (Vioxx), from the global market in 2004 following concerns about cardiovascular safety. Subsequent large-scale studies, including the Adenoma Prevention with Celecoxib trial and the Prostate Cancer Prevention Trial, provided further data on its risk-benefit profile. In 2005, the Food and Drug Administration convened an advisory committee which ultimately allowed it to remain on the market with strengthened warnings.

Society and culture

It has been a prominent subject in discussions about drug safety, pharmaceutical marketing, and regulatory oversight. The controversy surrounding the COX-2 inhibitor class led to congressional hearings involving the Food and Drug Administration and manufacturers. It has been featured in major media outlets like The New York Times and The Lancet. The drug is on the World Health Organization's List of Essential Medicines. In the United States, it was one of the most prescribed medications in its class, with significant sales for Pfizer. Its patent expiration and the subsequent introduction of generic versions, approved by bodies like the European Medicines Agency, have altered its market dynamics.